[{"address1": "One Kendall Square", "address2": "Building 600-700 Suite 6-401", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 468 1999", "website": "https://www.korrobio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.", "fullTimeEmployees": 92, "companyOfficers": [{"maxAge": 1, "name": "Mr. Nessan  Bermingham Ph.D.", "age": 50, "title": "Co-Founder & Independent Chairman of the Board", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 202137, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ram  Aiyar MBA, Ph.D.", "age": 45, "title": "CEO, President & Director", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 844866, "exercisedValue": 0, "unexercisedValue": 4357606}, {"maxAge": 1, "name": "Dr. Jean-Francois  Formela M.D., MBA", "age": 66, "title": "Co-Founder & Independent Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 8206, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vineet  Agarwal M.B.A.", "age": 41, "title": "Chief Financial Officer", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 811770, "exercisedValue": 0, "unexercisedValue": 1060249}, {"maxAge": 1, "name": "Mr. Andrew  Fraley Ph.D.", "title": "Co-Founder & Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joshua  Rosenthal Ph.D.", "title": "Co-Founder & Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Todd  Chappell M.B.A.", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeffrey M. Cerio J.D., Pharm.D.", "title": "Senior VP & General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Stephanie  Engels", "title": "Senior VP and Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Marco A. Passini Ph.D.", "title": "VP & Head of CNS biology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 33.0, "open": 32.47, "dayLow": 32.02, "dayHigh": 33.3082, "regularMarketPreviousClose": 33.0, "regularMarketOpen": 32.47, "regularMarketDayLow": 32.02, "regularMarketDayHigh": 33.3082, "forwardPE": -3.1926427, "volume": 53149, "regularMarketVolume": 53149, "averageVolume": 64261, "averageVolume10days": 76410, "averageDailyVolume10Day": 76410, "bid": 32.39, "ask": 33.58, "bidSize": 100, "askSize": 100, "marketCap": 306675072, "fiftyTwoWeekLow": 9.15, "fiftyTwoWeekHigh": 97.91, "fiftyDayAverage": 41.2128, "twoHundredDayAverage": 50.4152, "currency": "USD", "enterpriseValue": 187701920, "floatShares": 4436093, "sharesOutstanding": 9298820, "sharesShort": 253034, "sharesShortPriorMonth": 294950, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0272, "heldPercentInsiders": 0.06485, "heldPercentInstitutions": 0.91009, "shortRatio": 4.05, "shortPercentOfFloat": 0.0359, "impliedSharesOutstanding": 9298820, "bookValue": 21.345, "priceToBook": 1.5450926, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -85301000, "trailingEps": -9.19, "forwardEps": -10.33, "lastSplitFactor": "1:50", "lastSplitDate": 1699228800, "enterpriseToEbitda": -2.127, "52WeekChange": 1.4429629, "SandP52WeekChange": 0.34083736, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "KRRO", "underlyingSymbol": "KRRO", "shortName": "Korro Bio, Inc.", "longName": "Korro Bio, Inc.", "firstTradeDateEpochUtc": 1570109400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2796a462-87ad-3357-959a-ace1e7e2b1d2", "messageBoardId": "finmb_619256344", "gmtOffSetMilliseconds": -14400000, "currentPrice": 32.98, "targetHighPrice": 180.0, "targetLowPrice": 95.0, "targetMeanPrice": 123.75, "targetMedianPrice": 110.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 157434000, "totalCashPerShare": 16.931, "ebitda": -88268000, "totalDebt": 38461000, "quickRatio": 12.775, "currentRatio": 13.277, "debtToEquity": 19.417, "returnOnAssets": -0.31906998, "returnOnEquity": -0.62721, "freeCashflow": -62701876, "operatingCashflow": -69363000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-03"}]